Adma Biologics (ADMA) EBIT (2011 - 2026)

Adma Biologics (ADMA) has 13 years of EBIT data on file, last reported at $62.8 million in Q4 2025.

• Quarterly EBIT rose 63.74% year-over-year to $62.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $191.4 million (up 37.74% YoY) and the FY2025 annual result came in at $191.4 million, up 37.75% from the prior year.
• EBIT grew to $62.8 million in Q4 2025, from $51.0 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $62.8 million in Q4 2025 to a low of -$15.6 million in Q2 2021.
• A 5-year average of $12.7 million and a median of $4.1 million in 2023 frame the typical range for EBIT.
• Annual changes were most pronounced in 2021 — EBIT slipped 4.61% — and 2024, when it surged 8387.74%.
• Tracing ADMA's EBIT over 5 years: stood at -$13.2 million in 2021, then soared by 54.07% to -$6.1 million in 2022, then surged by 334.93% to $14.2 million in 2023, then jumped by 169.25% to $38.3 million in 2024, then jumped by 63.74% to $62.8 million in 2025.
• The last three EBIT figures came in at $62.8 million (Q4 2025), $51.0 million (Q3 2025), and $42.8 million (Q2 2025), per Business Quant data.